Purpose: To compare retrospectively two different techniques of Xen implantation, which are transconjunctival (ab-externo) and standard (ab-interno) techniques.
Methods: Forty-three eyes of 43 patients with primary open-angle glaucoma (POAG) who had Xen implantation operation via transconjunctival (ab-externo) technique comprised Group 1. Of the 43 patients, 20 (46.5%) were males and 23 (53.5%) were females. Their mean age was 61.76 ± 8.81 (41-74) years. Forty-four eyes of 44 patients with POAG who had Xen implantation operation via standard (ab-interno) technique comprised Group 2. Of the 44 patients, 21 (47.7%) were males and 23 (52.3%) were females. The mean age of this group was 63.80 ± 9.78 (38-75) years.
Results: Regarding age and sex, there were no significant differences between the groups (p > 0.05). The mean postoperative 1st day, 1st week, 1st month, 3rd month, 6th month, and 12th month IOPs were significantly lower than the mean preoperative IOP in both groups (p < 0.05). The mean number of anti-glaucomatous agents used postoperatively was significantly lower than the mean preoperative number for both groups (p < 0.05). There was a significantly smaller need for needling in the transconjunctival group (p < 0.05).
Conclusion: Xen implantation is a safe and effective method of reducing IOP and anti-glaucomatous dependence. Potential postoperative complications can be resolved easily. There were no significant differences between the standard method and the transconjunctival method in respect of IOP and re-use of anti-glaucomatous agents. However, there was a significantly smaller need for needling in the transconjunctival group. We recommend further studies to investigate long-term results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-020-01427-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes of Xen 45 gel stent implantation(Ab externo, open conjunctival approach) versus Trabeculectomy: A real world study.
Korean J Ophthalmol
December 2024
Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, South Korea.
Purpose: To compare the clinical outcomes of Xen 45 gel stent implantation surgery (Ab externo, open conjunctiva) with those of trabeculectomy.
Method: We retrospectively reviewed electronic medical record of 57patients (62eyes) treated with Xen implantation surgery (ab externo, open conjunctiva approach) between April 1st, 2021 and July 31st, 2023 by the same surgeon. Preoperative clinical data including intraocular pressure, the number of glaucoma medications, visual acuity were collected from 1 day to 12 months postoperatively.
Italian XEN-Glaucoma Treatment Registry (XEN-GTR): Effectiveness and Safety at 36 Months of XEN45 Implant.
J Clin Med
December 2024
Department of Surgical, Medical, Molecular Pathology and of Critical Care Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy.
: We evaluated the 3-year effectiveness and safety of XEN45, combined or not with phacoemulsification, in patients from the Italian XEN-Glaucoma Treatment Registry. : Data from glaucoma patients who underwent XEN45 alone or combined with phacoemulsification were analyzed. Changes in intraocular pressure (IOP) and the number of ocular hypotensive medications (OHMs) were tested with repeated measures ANOVA in last observation carried forward (LOCF) and per-protocol (PP) analyses.
View Article and Find Full Text PDFTransconjunctival XEN® 45 Gel Stent Implantation: Efficacy and Safety of a New Surgical Technique.
J Curr Glaucoma Pract
October 2024
Department of Ophthalmology, Hospital of San Severino Marche, AV3- Asur Marche, Macerata, Italy.
Article Synopsis
- This study aimed to assess the effectiveness and safety of a new surgical method called transconjunctival XEN® 45 gel stent implantation in treating primary open-angle glaucoma (POAG).
- A total of 31 patients underwent the procedure, experiencing an average decrease in intraocular pressure from 25.3 mm Hg pre-surgery to 15.9 mm Hg post-surgery, with most not needing additional medications by the one-month follow-up.
- The results suggest that this surgical technique is both safe and effective, offering a timely alternative for patients with POAG needing surgical intervention earlier in their treatment process.
Three-Year Results of XEN-45 Implantation for Glaucoma Secondary to Fuchs Uveitis Syndrome, Intermediate Uveitis, and Juvenile Idiopathic Arthritis-Related Anterior Uveitis.
Ocul Immunol Inflamm
November 2024
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
Purpose: To investigate the long-term outcomes of XEN-45 implantation for glaucoma secondary to Fuchs uveitis syndrome (FUS), juvenile idiopathic arthritis (JIA)-related anterior uveitis and intermediate uveitis (IU).
Methods: This retrospective study evaluated 19 eyes with FUS, 10 eyes with JIA, and nine eyes with IU that underwent XEN-45 Gel Stent implantation. The primary outcome measure was 3-year surgical success, defined as a ≥20% reduction in intraocular pressure (IOP), with a target IOP of 6-21 mmHg.
Efficacy of XEN gel stent implantation combined with mitomycin C injection in the treatment of open-angle glaucoma: a meta-analysis.
Int Ophthalmol
November 2024
Department of Ophthalmology, Zhongda Hospital Affiliated to Southeast University, Nanjing, China.
Objective: To assess the efficacy of XEN gel stent implantation combined with mitomycin C (MMC) injection in controlling intraocular pressure (IOP) and the dosage of postoperative medication for open-angle glaucoma (OAG) patients.
Methods: The PubMed, Embase, Cochrane Library, and Science Direct databases were searched from inception to August 2022 without any language restriction. All studies that compared IOP and the dose of medication before and after XEN gel stent implantation and MMC injection for OAG patients were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!